Navigation Links
Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM)
Date:12/6/2007

r to initiating the study and are considered binding.

Results

Pursuant to an SPA, the primary endpoint was defined as mean decrease in pain intensity scores between Remoxy and placebo during the 12-week treatment period. Top-line data indicates that the study achieved a statistically significant result in its primary endpoint (p<0.01). In addition, the study achieved statistically significant results in secondary endpoints such as Quality of Analgesia (p<0.01) and Global Assessment (p<0.01). No drug-related safety issues were noted in this study.

About ORADUR

ORADUR is a patented technology designed to transform drugs into sustained release oral products with the added benefit of being less prone to abuse.

About DURECT Corporation

DURECT Corporation is an emerging specialty pharmaceutical company developing pharmaceutical systems based on its proprietary drug delivery platform technologies. The Company currently has multiple late-stage pharmaceutical products in development addressing large markets in pain management, with a number of research programs underway targeting chronic disease and other therapeutic areas. For more information, please visit http://www.durect.com.

NOTE: ORADUR(TM) is a trademark of DURECT Corporation. Other referenced trademarks belong to their respective owners. Remoxy is a drug candidate under development and has not been submitted or approved for commercialization by the FDA or other health authorities.

DURECT Forward-Looking Statement

The statements in this press release regarding Remoxy, its expected New Drug Application filing date, attributes and commercial potential, and other potential ORADUR-based products are forward looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not
'/>"/>

SOURCE DURECT Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
2. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
3. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
6. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
7. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
8. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
9. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
10. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
11. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2008)...e-USNewswire/ -- Abnormalities in auditory and lan... autism spectrum disorder by using magnetoencephal...y at the annual meeting of the Radiological Societ...we can record the tiny magnetic fields associated ...rts, Ph.D., vice chair of research in the Departme...
(Date:11/28/2008)...ewswire-FirstCall/ -- Eli Lilly and Company,(NYSE...Application (sNDA) from,the U.S. Food and Drug Ad...),for the management of chronic pain. Lilly plans... 2009, adding data from a recently completed posit...nee. , The decision does not affect duloxet...
(Date:11/26/2008)... Children whose eyes are... increased risk of developing mental illness by ea...inic study published this month in Pediatrics , th...atrics. , , The retrospective study examine...mus (misaligned eyes) and compared them with recor...
(Date:11/26/2008)...ects , , FRANKLIN, Mass., Nov. 26 /PRNewswi...ard: PLCSF) announced today that it has received f...ation (FDA) for its U.S. pivotal trial to study th...(TM) and associated therapy in the prevention of ... FDA also approved PLC,s request to expand their i...
Breaking Medicine Technology:Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Eye Divergence in Children Triples Risk of Mental Illness 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Possible biological explanation for C Section linked allergies and asthma found 19976 1Possible biological explanation for C Section linked allergies and asthma found 19976 2Crdentia Announces 2008 First Quarter Results 19972 1Crdentia Announces 2008 First Quarter Results 19972 2Crdentia Announces 2008 First Quarter Results 19972 3Crdentia Announces 2008 First Quarter Results 19972 4Crdentia Announces 2008 First Quarter Results 19972 5Crdentia Announces 2008 First Quarter Results 19972 6Crdentia Announces 2008 First Quarter Results 19972 7FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 1FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 2FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 3FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 4Iraq war service 3A A risk factor for bronchiolitis 3F 19967 1Iraq war service 3A A risk factor for bronchiolitis 3F 19967 2
..., FL -- (MARKET WIRE) -- July 06, 2007 -- DOR BioP...://studio.financialcontent.com/Engine?Account=iwir...p://studio.financialcontent.com/Engine?Account=iwi...R" or the "Company") announced today that the Euro...7 B1, with claims related to,oral vaccination usin...
...ublished in The Lancet on TMC125, an Investigation... /PRNewswire/ -- Data from two,ongoing Phase 3 stu... HIV-1 adult patients with documented non-nucleosi...tease inhibitor (PI),resistance reached an undetec...ndetectable level < 50 HIV-1 RNA copies/mL) with,T...
Other Medicine Technology:DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 2DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 3DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 4DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 5DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 6TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 2TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 3TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 4
(Date:12/1/2008)... 1 This December, Anthem Blue,Cro...he Anthem Blue Cross,HealthFair Bus travels the s...,on Monday, December 1 from the Anthem offices in ...n a multi-city tour to include Los Angeles, Ventur...isco (see detailed schedule,below). , (Pho...
(Date:12/1/2008)...PRNewswire/ -- Question. What would happen if,we ...lding exercise? The,fitness world would certainly...rship fees would have to close. 2. Phony exercise ...t. 3. We would never have to spend another dime on...,s take-home pay is now estimated at 35 billion,d...
(Date:12/1/2008)...D Global Telemedicine, Inc. deploys telemedicine d...t program. 17 school sites in Sevier County, Tenne..., North Chelmsford, MA (PR...dicine & Cherokee Health Systems collaborated ...s in Sevier County, Tennessee. In addition to thi...
(Date:12/1/2008)...stage breast cancer who have undergone breast augm...l-breast radiation treatment called brachytherapy,...l meeting of the Radiological Society of North Ame...ave better cosmetic outcomes and avoid the risk of...ndergo whole-breast radiation therapy. , "We are...
Breaking Medicine News(10 mins):Health News:Anthem Blue Cross Gives the Gift of Health to California 2Health News:Anthem Blue Cross Gives the Gift of Health to California 3Health News:Push-Ups: 'It's Horizontal Jogging' 2Health News:Telemedicine Becoming More Relevant to Children's Health Within School Systems. 2Health News:Telemedicine Becoming More Relevant to Children's Health Within School Systems. 3Health News:Breast cancer treatment offers better outcome to women with implants 2
...2006 issue of General Dentistry, the AGD’s clinica...especially that of the tongue is harmful and shoul...e, the report describes the condition of a young g...was massive scar tissue formation around the area ...
... milk substitute, and a highly vulnerable commodit...ealth concerns determine what goes into formula mi.../ The Codex Alimentarius Commission, part of bot...of the United Nations and the World Health Organis...
...ched a $38 million project along with major region...u threat in Asia and the Pacific. // The Manila-b...e resources urgently needed to help control and re...us, and to increase the region's preparedness for ...
...ons (ASPS) reports say that plastic surgery was pe... The ethnic community opts for this surgery than ...nce their appearance or minimize the signs of agin...nd more people opted for it in the year 2005 with ...
Other Medicine News:
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
Medicine Products: